MedTrace Logo

Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial

NCT00133822 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-08-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether the administration of risperidone is effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant post-traumatic stress disorder (PTSD) in civilians.

Conditions

  • Post-Traumatic Stress Disorders

Interventions

DRUG

Sertraline and Risperidone

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Barbara O Rothbaum, PHD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133822 on ClinicalTrials.gov